ARS Pharmaceuticals short interest was 31.17% of the float on July 31st, according to new data we received from Benzinga. Short interest totaled 21,451,536 shares, which was a decrease of -5.37% from July 15th.
It is estimated that it would take 7.78 days for short sellers to buy back their shares, with current trading volumes.
ARS Pharmaceuticals Hedge Fund Activity
We have seen 112 institutional investors add shares of ARS Pharmaceuticals stock to their portfolio, and 105 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MILLENNIUM MANAGEMENT LLC removed 3,581,982 shares (-59.9%) from their portfolio in Q2 2026, for an estimated $28,691,675
- FRANKLIN RESOURCES INC removed 3,278,549 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $26,261,177
- CAPITAL WORLD INVESTORS added 2,754,931 shares (+inf%) to their portfolio in Q2 2026, for an estimated $22,066,997
- CASDIN CAPITAL, LLC removed 1,600,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $12,847,999
- SOUTHPOINT CAPITAL ADVISORS LP removed 1,500,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $12,044,999
- TYRO CAPITAL MANAGEMENT LLC added 1,490,738 shares (+50.2%) to their portfolio in Q2 2026, for an estimated $11,940,811
- BOOTHBAY FUND MANAGEMENT, LLC added 1,350,907 shares (+539.1%) to their portfolio in Q2 2026, for an estimated $10,820,765
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
ARS Pharmaceuticals Insider Trading Activity
ARS Pharmaceuticals insiders have traded $SPRY stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $SPRY stock by insiders over the last 6 months:
- ERIC KARAS (Chief Commercial Officer) sold 25,000 shares for an estimated $250,000
- ALEXANDER A FITZPATRICK (Chief Legal Officer) sold 3,355 shares for an estimated $33,550
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
ARS Pharmaceuticals Price Targets
Multiple analysts have issued price targets for $SPRY recently. We have seen 2 analysts offer price targets for $SPRY in the last 6 months, with a median target of $27.0.
Here are some recent targets:
- Roanna Ruiz from Leerink Partners set a target price of $24.0 on 06/25/2026
- Josh Schimmer from Cantor Fitzgerald set a target price of $30.0 on 05/28/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
